Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells

BACKGROUND: Bevacizumab is an antiangiogenic compound developed to target tumour vessels. Its off‐label use in ophthalmology requires in vitro testing on ocular cells. AIM: To quantify the antipermeability and antiproliferative effects of bevacizumab on cultured choroidal endothelial cells (CECs). I...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Peters, Swaantje, Julien, Sylvie, Heiduschka, Peter, Grisanti, Salvatore, Ziemssen, Focke, Adler, Martin, Schraermeyer, Ulrich, Bartz‐Schmidt, Karl‐Ulrich
Format: Artigo
Idioma:Inglês
Publicat: BMJ Group 2007
Matèries:
Extended Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1955593/
https://ncbi.nlm.nih.gov/pubmed/17179166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bjo.2006.109702
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars